Skip to main content
OpenTrials
Completed

NCT Number: NCT06505902

Pulmonary Diffusing Capacity During Incremental Exercise in COPD

Background:

The combined measurement of pulmonary diffusing capacity for carbon monoxide (CO) and nitric oxide (NO) (DL,CO,NO) has recently been standardized and validated for clinical use. It involves a noticeably short breath-hold time (≤5 seconds), making it feasible to perform on patients with chronic obstructive pulmonary disease (COPD). These patients have lower diffusing capacity and are unable to increase it during exercise, which is thought to be caused by changes in pulmonary perfusion potentially leading to exertional dyspnea. The aim of the present study is to examine whether pulmonary diffusing capacity for incremental exercise differs between patients with COPD and matched healthy controls.

Methods:

Inclusion of 12 individuals with mild-to-severe COPD and 12 healthy age- and sex-matched controls.

Design: Case-control study

Intervention: DL,CO,NO and arterial blood gases will be measured during exercise at a bicycle ergometer at 0, 20, 40, 60 and 80% of the individual's maximal workload.

Sample size: To detect a 15 mmol min-1 kPa-1 difference in DL,NO between groups at 60% of maximal workload, with a power of 90% and a significance level of 0.05, at least 12 subjects are required in each group. To account for potential dropouts, power will be permitted to decrease to 80%, corresponding to a total of 10 subjects in each group.

Statistical design: Linear mixed effect model and pairwise testing of estimated marginal means.

Perspective: This study will add to the understanding exertional dyspnoea in patients with COPD.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Aktiv Sundhed (CFAS), Rigshospitalet, Copenhagen, Denmark.

Copenhagen, København Ø, 2100, Denmark

About this study

Introduction and background A pattern that applies to the majority of the more than 250 million people who suffer from chronic obstructive pulmonary disease (COPD) worldwide, is a downward spiral of exertional dyspnoea to poor quality of life, invalidity, and early death. A critical mechanism of exertional dyspnoea in these patients is thought to be reduced alveolar-capillary reserve, that is, a reduced ability to recruit and distend the pulmonary capillary bed to increase diffusing capacity upon an increase in cardiac output, which may be assessed by measuring the dual test pulmonary diffusing capacity (DL,CO,NO) during exercise. This technique permits up to 12 repeated manoeuvres within a session without affecting measurements, and it is thus ideal for assessing acute changes in pulmonary diffusing capacity and its components during various physiological manoeuvres. With this technique, the investigators have recently documented that alveolar-capillary recruitment, assessed by the change in the pulmonary diffusing capacity for nitric oxide (DL,NO) at a fixed workload of 60% of maximum, is blunted in COPD, seemingly in a severity-dependent fashion (unpublished observations). However, it is unknown whether this is already evident at low workloads, and/or whether it persists at near-maximal workloads, and it remains to be established to which extent this has an impact on pulmonary gas exchange, conventionally measured by the alveolar-arterial oxygen difference.

Aim The overall aim is to determine whether and how alveolar-capillary recruitment during incremental exercise differs between patients with mild-to-moderate COPD and healthy individuals.

Study design and recruitment 12 patients with mild-to-moderate COPD and 12 healthy age- and sex-matched controls will be included in the study, where DL,CO,NO will be measured at rest and during incremental workloads. Visit 0 consist of medical health interview and brief examination including blood pressure, heart rate and ECG measurement to investigate inclusion and exclusion criteria. Baseline measurements (Visit 1) will be performed to assess fitness and cardiopulmonary health status for the included patients and participants. The baseline measurements include cardiopulmonary exercise testing, lung function testing (dynamic spirometry, whole-body plethysmography and 10-second single-breath diffusing capacity for carbon monoxide), and an assessment of body composition. On Visit 2, which is at least two days later, an arterial catheter is inserted, after which DL,CO,NO and arterial blood gases are measured at rest, and at 20, 40, 60, and 80% of maximal workload on a bicycle ergometer, as determined during the cardiopulmonary exercise text on Visit 1.

Sample size Based on unpublished data in which a difference in DL,NO (mmol min-1 kPa-1) between COPD and control at 60% of maximal workload during cycling exercise, the power calculation was based on a two-sided independent samples t-test, with a power of 90% and a significance level (alpha) of 0.05. To detect a 15 mmol min-1 kPa-1 difference in DL,NO between groups at 60% of maximal workload, with a power of 90% and a significance level of 0.05, at least 12 subjects are required in each group. To account for potential dropouts, power will be permitted to decrease to 80%, corresponding to a total of 10 subjects in each group.

Statistical procedure The investigators will perform a linear mixed effect model with group and time as factors with participant as random effect accounting for repeated measures. The investigators will then perform pairwise testing of estimated marginal means from our mixed effect model to test for between group differences and within group differences. The investigators will perform Holm correction due to multiple testing.

General information This study is novel as it investigates pulmonary capillary recruitment in COPD, which is thought to be an important mechanism of exertional dyspnoea, which have primarily only been discussed in theoretical terms in previous studies. This study will be conducted in accordance with the regional ethical committee and the Declaration of Helsinki. Informed consent will be obtained from all study participants before enrolment and baseline testing.

Significance, novelty and expected impact The physiological assessments that are evaluated in the present study have the potential to be used provide information on the cause of dyspnoea in the individual COPD patient. This is relevant for the understanding of basic respiratory physiology and for designing future studies with interventions that aim to affect pulmonary capillary recruitment in COPD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for COPD patients

  • Men and women
  • 40-80 years
  • Mild to severe COPD (GOLD stage I to IIII)

Inclusion criteria

for healthy participants

  • Men and women
  • Age +/- 3 years of an included COPD patient

Exclusion criteria

for COPD patients

  • Known ischaemic heart disease
  • Known heart failure
  • Cardiac arrythmias
  • Dementia or other severe neurological disease
  • Known vascular ischaemic disease
  • Symptoms of infection (bacterial/viral) within 2 weeks prior to the study
  • Pregnancy

Exclusion criteria

for heathy controls

  • COPD
  • Known ischaemic heart disease
  • Known heart failure
  • Cardiac arrythmias
  • Dementia or other severe neurological disease
  • Known vascular ischaemic disease
  • Symptoms of infection (bacterial/viral) within 2 weeks prior to the study
  • Pregnancy

Treatment and study plan

Exercise

Other

Exercise by bicycle and performing diffusing capacity measurements at the same time with arterial blood gasses.

Primary outcomes

  1. Primary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in DL,NO from rest to exercise as a function of workload

Secondary outcomes

  1. Key secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change of the alveolar-arterial oxygen difference from rest to exercise as a function of workload

  2. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in DL,NO from rest to exercise as a function of VO2

  3. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change of the alveolar-arterial oxygen difference from rest to exercise as a function of VO2

  4. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in cardiac output from rest to exercise as a function of workload

  5. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in stroke volume from rest to exercise as a function of workload

  6. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in heart rate from rest to exercise as a function of workload

  7. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in mean arterial blood pressure from rest to exercise as a function of workload

  8. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in cardiac output from rest to exercise as a function of VO2

  9. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in stroke volume from rest to exercise as a function of VO2

  10. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in heart rate from rest to exercise as a function of VO2

  11. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in mean arterial blood pressure from rest to exercise as a function of VO2

  12. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in PaO2 from rest to exercise as a function of workload and VO2

  13. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in SaO2 from rest to exercise as a function of workload and VO2

  14. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in PaCO2 from rest to exercise as a function of workload and VO2

  15. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in pH from rest to exercise as a function of workload and VO2

  16. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in base excess from rest to exercise as a function of workload and VO2

  17. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in lactate from rest to exercise as a function of workload and VO2

  18. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in respiratory rate from rest to exercise as a function of workload and VO2

  19. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in DL,CO,5s from rest to exercise as a function of workload and VO2

  20. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in DM from rest to exercise as a function of workload and VO2

  21. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in VC from rest to exercise as a function of workload and VO2

  22. Other secondary outcome

    Time frame: Measured at day 2

    Between-group difference in the change in VA from rest to exercise as a function of workload and VO2

Other outcomes

  1. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in time constant (phase 2) (s) from VO2kinetics

  2. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in mean response time (s) from VO2kinetics

  3. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in amplitude (mLO2/min) from VO2kinetics

  4. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in steady state gain (mLO2•min-1•watt-1) from VO2kinetics

  5. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in time delay (phase 1) (s) from VO2kinetics

  6. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in relative (mL/kg/min) VO2peak

  7. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in absolute (mL/min) VO2peak

  8. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in ventilatory threshold (%)

  9. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in ventilatory reserve (%)

  10. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in resistance (Rrs, R5-R20) measured by IOS

  11. Exploratory outcomes

    Time frame: Measured at day 2

    Between-group difference in reactance (Xrs, X5) measured by IOS

  12. Exploratory outcomes

    Time frame: Measured at day 2

    Between group difference in mean arterial pressure (MAP) as a function of workload.

  13. Exploratory outcomes

    Time frame: Measured at day 2

    Between group difference in systolic blood pressure (SBP) as a function of workload.

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

Pulmonary Diffusing Capacity During Incremental Exercise in COPD: A Case-Control Study

Acronym: DiffLung3

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 17, 2024
Registry last updated
Apr 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.